Celcuity Inc.: Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported
Vicky Hahne Kostenloser Wertpapierhandel Robert Uhl Brian Sullivan Exchange Commission On Celcuity Inc
Source: finanznachrichten.de